These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 6101523)

  • 1. Low neuroleptic serum levels in patients receiving fluphenazine decanoate.
    Tune LE; Creese I; Coyle JT; Pearlson G; Snyder SH
    Am J Psychiatry; 1980 Jan; 137(1):80-2. PubMed ID: 6101523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroleptic serum levels measured by radioreceptor assay in patients receiving intramuscular depot neuroleptics. Some preliminary findings.
    Turbott J; Villiger J; Hunter L
    Br J Psychiatry; 1985 Apr; 146():439-42. PubMed ID: 4016448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relapse in chronic schizophrenics treated with fluphenazine decanoate is associated with low serum neuroleptic levels.
    Jayaram G; Coyle J; Tune L
    J Clin Psychiatry; 1986 May; 47(5):247-8. PubMed ID: 3700342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum neuroleptic levels and clinical outcome in schizophrenic patients treated with fluphenazine decanoate.
    Brown WA; Silver MA
    J Clin Psychopharmacol; 1985 Jun; 5(3):143-7. PubMed ID: 3998204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monitoring plasma levels of fluphenazine during chronic therapy with fluphenazine decanoate.
    Miller RS; Peterson GM; McLean S; Westhead TT; Gillies P
    J Clin Pharm Ther; 1995 Apr; 20(2):55-62. PubMed ID: 7650075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroleptic serum levels measured by radioreceptor assay and clinical response in schizophrenic patients.
    Tune LE; Creese I; DePaulo JR; Slavney PR; Snyder SH
    J Nerv Ment Dis; 1981 Jan; 169(1):60-3. PubMed ID: 6108981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma levels of neuroleptic in patients receiving depot fluphenazine.
    Cohen BM; Waternaux C; Chouinard G; Sommer BR; Jones B
    J Clin Psychopharmacol; 1985 Dec; 5(6):328-32. PubMed ID: 4066997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A double-blind comparative trial of the decanoates of clopenthixol and fluphenazine in the treatment of chronic schizophrenic out-patients.
    Walker CA
    Pharmatherapeutica; 1983; 3(5):289-93. PubMed ID: 6133287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Haloperidol decanoate as a replacement for maintenance therapy with intramuscular fluphenazine decanoate in schizophrenia and other chronic psychoses.
    Roose K
    Acta Psychiatr Belg; 1982; 82(2):216-23. PubMed ID: 7180558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma levels of parent drug and metabolites in patients receiving oral and depot fluphenazine.
    Marder SR; Van Putten T; Aravagiri M; Hubbard JW; Hawes EM; McKay G; Midha KK
    Psychopharmacol Bull; 1989; 25(3):479-82. PubMed ID: 2626520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma fluphenazine levels by radioimmunoassay in schizophrenic patients treated with depot injections of fluphenazine decanoate.
    Wiles DH; Gelder MG
    Adv Biochem Psychopharmacol; 1980; 24():599-602. PubMed ID: 7405678
    [No Abstract]   [Full Text] [Related]  

  • 12. Blood and plasma kinetics of cis(Z)-clopenthixol and fluphenazine in psychiatric patients after intramuscular injection of their decanoic esters.
    Viala A; Hou N; Ba B; Durand A; Dufour H; D'Agostino N; Berda C; Jørgensen A
    Psychopharmacology (Berl); 1984; 83(2):147-50. PubMed ID: 6146995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma levels of fluphenazine decanoate. Effects of site of injection, massage and muscle activity.
    Soni SD; Wiles D; Schiff AA; Bamrah JS
    Br J Psychiatry; 1988 Sep; 153():382-4. PubMed ID: 3250675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia.
    Chouinard G; Annable L; Campbell W
    J Clin Psychopharmacol; 1989 Aug; 9(4):247-53. PubMed ID: 2570086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
    Midha KK; Hubbard JW; Marder SR; Marshall BD; Van Putten T
    J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum neuroleptic levels during reduced dose fluphenazine decanoate maintenance therapy.
    Heresco-Levy U; Greenberg D; Lerer B; Javitt DC; Brown WA
    Isr J Psychiatry Relat Sci; 1997; 34(4):281-9. PubMed ID: 9409085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluphenazine decanoate and fluphenazine enanthate in the out-patient management of chronic schizophrenia.
    MacCrimmon DJ; Saxena B; Foley P; Grof P
    Neuropsychobiology; 1978; 4(6):360-5. PubMed ID: 692838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparative study of pipothiazine palmitate and fluphenazine decanoate in the maintenance of remission of schizophrenia.
    Leong OK; Wong KE; Tay WK; Gill RC
    Singapore Med J; 1989 Oct; 30(5):436-40. PubMed ID: 2575796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Depot neuroleptic medication and serum levels by radioreceptor assay: prolactin concentration, electrocardiogram abnormalities and six-month outcome.
    Turbott J; Villiger J; Hunter L
    Aust N Z J Psychiatry; 1987 Sep; 21(3):327-38. PubMed ID: 3435373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia.
    Gitlin M; Nuechterlein K; Subotnik KL; Ventura J; Mintz J; Fogelson DL; Bartzokis G; Aravagiri M
    Am J Psychiatry; 2001 Nov; 158(11):1835-42. PubMed ID: 11691689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.